Prostate Cancer News on BioPortfolio

FDA Approves CastrationSensitive Prostate Cancer Drug

Officials with the FDA have granted approval to abiraterone acetate Zytiga tablets in combination with prednisone for the treatment of metastatic highrisk castrationsensitive prostate cancer CSPC according to a press release.

FDA Approves Abiraterone for HighRisk Prostate Cancer

The FDA has approved abiraterone acetate in combination with prednisone and androgen deprivation therapy for highrisk patients with metastatic hormonenaïve prostate cancer or newlydiagnosed metastatic hormonesensitive prostate cancer.

FDA Approves Abiraterone Plus ADT for HighRisk Prostate Cancer

The FDA has approved abiraterone acetate in combination with prednisone and androgen deprivation therapy for highrisk patients with metastatic hormonenaïve prostate cancer or newlydiagnosed metastatic hormonesensitive prostate cancer.

QUOTED. Feb. 8 2018. Sean Boyd.

Check out what US FDA&39;s Sean Boyd had to say about the benefits to industry of the device center&39;s creation...&160;&160;&160;

Pages